Compare MQ & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MQ | FTRE |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2021 | N/A |
| Metric | MQ | FTRE |
|---|---|---|
| Price | $4.01 | $10.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $5.43 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 3.4M | 1.6M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $588,561,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $25.90 | $3.21 |
| Revenue Next Year | $17.88 | $0.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.11 | 1.88 |
| 52 Week Low | $3.48 | $3.97 |
| 52 Week High | $7.04 | $18.67 |
| Indicator | MQ | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 24.50 |
| Support Level | $3.99 | $9.20 |
| Resistance Level | $4.46 | $15.00 |
| Average True Range (ATR) | 0.15 | 1.32 |
| MACD | 0.01 | -0.73 |
| Stochastic Oscillator | 20.95 | 13.58 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.